Axonics Modulation Technologies has gained $38.5 million in a Series B round to start a study of its overactive bladder implant in Europe and North America early next year.
After gaining its lead asset from GlaxoSmithKline, AltheRx Pharmaceuticals has made a series of leadership changes through a restructuring plan that features a $15 million investment led by Becker Ventures.
Taris Biomedical has gone back to the venture well as the biotech startup launches a midstage study of its lead candidate against bladder pain. The Lexington, MA-based company found support for its latest financing from previous backers at Flybridge Capital Partners, Flagship Ventures, Polaris Venture Partners and Third Rock Ventures.
Researchers at the Institute of Plastics Processing (IKV) at RWTH Aachen University in Germany are developing a controlled-release foam that can deliver drugs to treat diseases such as overactive bladder.
Astellas is one step closer to building its blockbuster business in overactive bladder meds.
Antares Pharma's ($AIS) new topical gel to treat overactive bladder will hit the U.S. commercial market in the spring. FDA approval for the drug variation was announced Dec. 8. Fellow New Jersey